Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, and Vincristine
About
Membership operator: AND
Therapies: 5
Therapies
Cyclophosphamide (tx:ncit:C405)
Doxorubicin (tx:ncit:C456)
Prednisone (tx:ncit:C770)
Rituximab (tx:ncit:C1702)
Vincristine (tx:ncit:C933)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (4) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine | |
| FDA (2) | CD20 + | Diffuse Large B-Cell Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine | |
| FDA (2) | CD20 + | Burkitt Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine | |
| FDA (2) | CD20 + | Mature B-Cell Neoplasms | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine |